WO2000078811A1 - Variants d'antithrombine humaine - Google Patents
Variants d'antithrombine humaine Download PDFInfo
- Publication number
- WO2000078811A1 WO2000078811A1 PCT/JP2000/004101 JP0004101W WO0078811A1 WO 2000078811 A1 WO2000078811 A1 WO 2000078811A1 JP 0004101 W JP0004101 W JP 0004101W WO 0078811 A1 WO0078811 A1 WO 0078811A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- human antithrombin
- amino acid
- antithrombin
- heparin
- mutant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8128—Antithrombin III
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to an artificial human anti-thrombin mutant having a high protease inhibitory activity even in the absence of heparin. More specifically, the present invention relates to a mutant obtained by modifying the three-dimensional structure of a natural human antithrombin molecule by genetic manipulation, and to a human antithrombin mutant having a three-dimensional structure after heparin binding.
- the mutant can be used, for example, for the treatment of DIC thrombotic diseases and toxemia of pregnancy.
- antithrombin II is hereinafter referred to as antithrombin.
- Natural human antithrombin is a single-chain glycoprotein with a molecular weight of 58,000, which has protease inhibitory activity in the blood coagulation system. Natural human antithrombin is biosynthesized as a precursor protein consisting of 464 amino acid residues.However, during the secretion process, the signal peptide part consisting of 32 residues is cleaved off, resulting in the invasion of blood vessels. The circulating mature human antithrombin is composed of 432 amino acid residues.
- Natural human antithrombin like i-antitrypsin and heparin cofactor II, is a plasma protein belonging to the Serpins superfamily. Thrombin, activated factor X (factor Xa), activated IX (factor IXa) It is a major regulator of the coagulation system that controls the activity of major coagulation enzymes. Naturally occurring human antithrombin having such pharmacological activities can correct abnormal hypercoagulability, specifically, toxicosis predominantly characterized by intravascular coagulation syndrome (DIC), hypertension during pregnancy, proteinuria, and edema. It is used to treat thrombophilia due to congenital human antithrombin deficiency.
- DIC intravascular coagulation syndrome
- natural human antithrombin molecules have a large number of strands composed of antiparallel / 3-sheets (slA ⁇ ) which are roughly classified into three directions, ⁇ , ⁇ and C. It is a protein composed of nine ⁇ -helices (abbreviated as hA to hI) and a coil structure (Stein PE, Carrel 1 RW, Nature Struct Biol 2:96 1995). Recently, the X-ray crystal structures at 2.6 A resolution of native and latent forms of antithrombin dimer (Skinner K., et al., J. Mol. Biol.
- human antithrombin is an ⁇ incomplete '' serpin as an inhibitor in the absence of heparin, and in the presence of heparin For the first time I thought it would be a "complete" inhibitor.
- One or more of the amino acids at positions 9, 9, 96, 135, 155, 192, 393 and 394 are converted to other amino acids. Further, a human antithrombin mutant has been disclosed (Japanese Patent Application Laid-Open No. H2-262598). Also, 11th to 14th,
- At least one amino acid in each of the four regions at positions 41 to 47, 125 to 133, and 384 to 398 is at least one in each region, alone or in combination.
- a human antithrombin mutant that has been converted to a homolog is disclosed (JP-A-5-339292). However, the efficacy of these mutants is not always sufficient, and it is desired to produce human antithrombin mutants that have stronger protease inhibitory activity in the absence of heparin.
- An object of the present invention is to provide a novel human antithrombin mutant that functions as a complete inhibitor in the absence of heparin and has high protease inhibitory activity.
- Arg393 moves about 70 people from end to end of the human antithrombin molecule with protease. This dynamic change is thought to be important for stable complex formation with protease.
- the presence of a latent form inserted into the molecule as s4A is known even though the reaction site is not cleaved.
- the formation of s 4 A is considered to be a stable structure of serpins.
- the reaction loop of natural ⁇ -antitrypsin is completely exposed on the surface of the molecule, and the side chain of Pet Met358 is oriented to the outside of the molecule.
- the conformation complementary to the active site of serine protease (conformation) which has high reactivity with protease, and is likely to cause intramolecular insertion of the reaction loop after cleavage.
- the side chain of Pg Arg393 of natural human antithrombin is oriented inside the molecule, its reactivity with protease is extremely low (Jin L., et al., Proc. Natl. Acad. Sci. USA, 94: 14683, 1997).
- the present inventor has previously described human antithrombin, analyzing the conformational changes for each reaction loop of plasminogen ⁇ lipped base a pair inhibitor development 1 and alpha iota _ anti trypsin, by studying the natural human Toanchi P14 position (Ser380) in thrombin functions as a complete inhibitor in the absence of heparin and is high It was determined to be an important site for producing an appropriate three-dimensional structure having protease inhibitory activity. Furthermore, the present inventors have proposed that the positions P15 to P10 in the natural human antithrombin reaction loop are referred to as a proximal hinge region (proximal hinge). It was investigated.
- this proximal hinge region plays the role of hinge (hinge) when the reaction loop enters as s4A, its base, P16 (Glu378), has the same high protease inhibitory activity as P14. It was determined to be a site to be converted to an appropriate amino acid in order to produce a human antithrombin mutant having an appropriate tertiary structure having
- the natural human anti-thrombin reaction loop is cleaved by protease, it is inserted into the molecule as s4A between s3A and s5A, and the region involved in opening between these strands Is known to be a shutter region centered on hB (Ser79 to Thr90) (Stein PE, Carrell RW, Nature Struct Biol 2:96, 1995).
- the gap between s3A and s5A is opened, the inventor first cuts off the hydrogen bond between both strands, and then these strands slide on the groove of hB, and the "easy to open" was found to be related to the ease of entry of the reaction loop.
- the shutter region of natural human antithrombin is an important region that affects the opening and closing between s3A and s5A, and also affects the binding to heparin and the activity of antithrombin. It was concluded that a human antithrombin mutant having an appropriate three-dimensional structure having high protease inhibitory activity could be prepared by converting the 8th position (Leu78), which corresponds to the above, into another amino acid.
- the present inventors analyzed and studied the dynamic structural change of natural human antithrombin and the promotion of protease inhibitory activity by heparin binding, particularly the three-dimensional structure of each amino acid in the heparin binding region.
- the heparin-binding region in natural human antithrombin has been developed by antithrombin Toyama (Koide T., Takahashi K., et al., Pro atl. Acad. Sci.) In which Arg at position 47 has been converted to Cys. .USA, 81: 289, Analysis of abnormal cases such as 1984), chemical modification experiments, and analysis of site-specific mutants have revealed that these are basic amino acid residues present in hA and hD.
- the N-terminal portion of human antithrombin plays a role as a three-dimensional gate that stabilizes the antithrombin-pentapentahlide complex when it is bound by pen saccharide. (Fitton, HL, et al., Protein science 7: 782, 1998). Comparing the three-dimensional structures of native and latent forms of native human antithrombin, the hD of the native form is slightly twisted, and the heparin binding sites Arg47, Lys25 and Lysl25.
- Argl29 point in the direction of the pentasadlide bond region, and the ⁇ group of the Argl29 forms a hydrogen bond with the side chain of Asp278 to stabilize the side chain, thereby forming the pentasadlide sulfate. It facilitates ionic interaction with the group.
- hD elongates immediately, Arg47 hydrogen bonds with Serl12, Lysl25 hydrogen bonds with Ile7, and is a region of amino acid residues important for heparin binding. Are not all oriented in the direction of the heparin binding region (Skinner R., et al., J. Mol. Biol. 266: 601, 1997).
- the present inventor has determined that by pre-cutting the hydrogen bond between Argl29 and Asp278, it is possible to change the three-dimensional structure similar to that in the presence of heparin even in the absence of heparin. Where it is hydrogen bonded to Argl29
- the present inventor examined the information on the dynamic structural change of antithrombin due to heparin binding of natural human antithrombin analyzed so far, and found that the protease inhibitory activity of natural human antithrombin was A conversion site on the steric structure that is preferable for promotion was derived. That is, by appropriately converting the hinge region of the reaction loop of natural human antithrombin, the hinge region during s4A formation, and the site related to heparin binding to one or two or more other amino acids, an appropriate protease inhibitory activity is obtained. It was concluded that a human antithrombin mutant having a unique three-dimensional structure could be produced.
- the present inventors have conducted intensive studies on the improvement of the human antithrombin mutant, and as a result, succeeded in producing a novel human antithrombin mutant having an appropriate three-dimensional structure having high protease inhibitory activity, and completed the present invention. Done.
- the present invention relates to a mutant of natural human antithrombin, wherein the amino acid sequence at positions 78, 278, 378 and
- human antithrombin variant characterized in that at least one of the amino acids at position 380 has been converted to another amino acid.
- the present invention comprises a DNA encoding the above human antithrombin mutant.
- FIG. 1 shows the construction of an AT recombinant mutant expression vector (example of Ser380His).
- novel human antithrombin mutant of the present invention produced a mutant similar to the three-dimensional structure after heparin binding by site-directed mutagenesis.
- Neomycin resistant stably expressing cells were selected with G418 and pooled.
- a pulsed one-thirds experiment was performed using a pool of stably expressed BHK (baby hamster kidney) cells. 5 ⁇ 10 5 cells were seeded on a 35 mm diameter dish and cultured.
- CM culture supernatant
- CE cell extract
- CM For mutants with high secretion, CM after 8 hours of chase was collected. Add thrombin or factor Xa to the recovered solution 500 ⁇ 1, and in the absence of heparin, at 37 ° C for 5 minutes and 60 minutes.In the presence of heparin, react for 5 minutes and immunoprecipitate, 10% The amount of the complex was determined by SDS-PAGE (+ SH).
- Table 1 summarizes the secretivity of each antithrombin recombinant mutant from BHK cells. The figure shows the intracellular and secretory amounts 8 hours after the chase when the radiation dose at the time of pulse labeling was set to 100%, whereas the secretion amount of the natural recombinant was 89%.
- the Leu78Phe mutant in which Leu at position 78 was converted to Phe had 90% secretion.
- Asp at position 278 is converted to Ala, Gly, His, or Tyr (Asp278Ala, Asp278Gly, Asp278His, or Asp278Tyr)
- the natural recombinant is 104%, 104%, 165%, or 160%, respectively. Secretion more than the body was obtained.
- mutants in which Asp at position 278 was converted to Arg, Asn, or Val had 57%, 48%, or 51% secretion, respectively.
- Mutants in which Ser at position 380 has been converted to Ala, Arg, Asn, Asp, Gly, His, Pro. Thr, Tyr or Val (Ser380Ala, Ser380Arg, Ser380Asn, Ser380Asp, Ser380Gly, Ser380His, Ser380Pro, Ser380Thr, Ser380Tyr or Ser380Val) produced good secretion properties, but the mutants converted to Asn and Val showed high secretion rates of 154% and 144%, respectively.
- TAT thrombin
- Table 2 summarizes the results of examining the ability of each antithrombin recombinant mutant to form a complex with thrombin (TAT).
- TAT thrombin
- mutants shown in Table 2 were similar to the naturally-occurring recombinants (Leu78Phe, Asp278His and Ser380Ala mutants) in the long-term (120 minutes) interaction with thrombin, or were naturally-occurring. More than the mutant (Asp278Ala, Asp278Val, Asp278Tyr, Ser380Gly and Ser380Tyr mutants) had a stable TAT-forming ability.
- Table 3 summarizes the results of examining the ability of each antithrombin recombinant mutant to form a complex with factor Xa (Xa-AT).
- the maximum effect of the present invention that is, the immediate Xa-AT-forming ability in the absence of heparin, was determined by comparing the relative value of the natural recombinant to the Xa-AT-forming ability of 100% with Leu at position 78. In the Leu78Phe mutant that has been converted to Phe, it was 106%.
- the mutant In the Asp278Gly, Asp278His, or Asp278Tyr mutant in which Asp at position 278 has been converted to Gly, His, or Tyr, the mutant is 144%, 171%, or 131%, respectively, all of which have higher performance than the natural recombinant.
- Strange A variant has been obtained.
- native recombinant comparable Leu78Phe, Asp278Gly, Asp278His and Ser380 Tyr mutant
- natural recombinant or more As P 278Val , Asp278Tyr and Ser380 Gly mutant.
- the Ser380Tyr 1 72 122 1 11 value is a relative value with the TAT-forming ability of the natural recombinant AT being 100%.
- Ser380Tyr 86 90 105 values are relative to the natural recombinant AT, with the Xa-AT formation ability of 100%, Industrial applicability
- the present invention it is possible to provide a novel human antithrombin mutant having an appropriate three-dimensional structure having high protease inhibitory activity even in the absence of heparin.
- the recombinant human antithrombin mutant of the present invention is useful, for example, as a therapeutic drug for thrombotic diseases and toxemia of pregnancy.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/018,815 US7001993B1 (en) | 1999-06-23 | 2000-06-22 | Human antithrombin variants |
EP00940809A EP1225184B1 (en) | 1999-06-23 | 2000-06-22 | Human antithrombin variants |
CA2375224A CA2375224C (en) | 1999-06-23 | 2000-06-22 | Human antithrombin variants |
DE60038310T DE60038310T2 (de) | 1999-06-23 | 2000-06-22 | Menschliche antithrombin-varianten |
AU55681/00A AU776796B2 (en) | 1999-06-23 | 2000-06-22 | Human antithrombin variants |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP17696799A JP4339962B2 (ja) | 1999-06-23 | 1999-06-23 | ヒトアンチトロンビン変異体 |
JP11/176967 | 1999-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000078811A1 true WO2000078811A1 (fr) | 2000-12-28 |
Family
ID=16022851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/004101 WO2000078811A1 (fr) | 1999-06-23 | 2000-06-22 | Variants d'antithrombine humaine |
Country Status (10)
Country | Link |
---|---|
US (1) | US7001993B1 (ja) |
EP (1) | EP1225184B1 (ja) |
JP (1) | JP4339962B2 (ja) |
KR (2) | KR100832733B1 (ja) |
AT (1) | ATE388965T1 (ja) |
AU (1) | AU776796B2 (ja) |
CA (1) | CA2375224C (ja) |
DE (1) | DE60038310T2 (ja) |
ES (1) | ES2303508T3 (ja) |
WO (1) | WO2000078811A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7548849B2 (en) | 2005-04-29 | 2009-06-16 | Research In Motion Limited | Method for generating text that meets specified characteristics in a handheld electronic device and a handheld electronic device incorporating the same |
US7962857B2 (en) | 2005-10-14 | 2011-06-14 | Research In Motion Limited | Automatic language selection for improving text accuracy |
US8948741B2 (en) | 2009-09-24 | 2015-02-03 | Wave Guard Technologies Ltd. | System and method of online radiation management and control of non-ionizing radiation sources |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0384122A2 (de) * | 1989-01-24 | 1990-08-29 | BEHRINGWERKE Aktiengesellschaft | Mutanten von humanem Antithrombin III |
WO1991000291A1 (en) * | 1989-06-26 | 1991-01-10 | Akzo N.V. | Serpin variants |
EP0568833A1 (en) * | 1992-04-10 | 1993-11-10 | Eisai Co., Ltd. | Human antithrombin III mutants |
JPH0971600A (ja) * | 1995-09-06 | 1997-03-18 | Eisai Co Ltd | ヒトアンチトロンビンiii 変異体 |
WO1999064568A1 (fr) * | 1998-06-08 | 1999-12-16 | Universite De Nantes | Kit d'encapsidation |
-
1999
- 1999-06-23 JP JP17696799A patent/JP4339962B2/ja not_active Expired - Fee Related
-
2000
- 2000-06-22 KR KR1020077012014A patent/KR100832733B1/ko not_active IP Right Cessation
- 2000-06-22 US US10/018,815 patent/US7001993B1/en not_active Expired - Fee Related
- 2000-06-22 EP EP00940809A patent/EP1225184B1/en not_active Expired - Lifetime
- 2000-06-22 AT AT00940809T patent/ATE388965T1/de active
- 2000-06-22 CA CA2375224A patent/CA2375224C/en not_active Expired - Fee Related
- 2000-06-22 ES ES00940809T patent/ES2303508T3/es not_active Expired - Lifetime
- 2000-06-22 KR KR1020017016463A patent/KR100798285B1/ko not_active IP Right Cessation
- 2000-06-22 DE DE60038310T patent/DE60038310T2/de not_active Expired - Lifetime
- 2000-06-22 AU AU55681/00A patent/AU776796B2/en not_active Ceased
- 2000-06-22 WO PCT/JP2000/004101 patent/WO2000078811A1/ja active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0384122A2 (de) * | 1989-01-24 | 1990-08-29 | BEHRINGWERKE Aktiengesellschaft | Mutanten von humanem Antithrombin III |
WO1991000291A1 (en) * | 1989-06-26 | 1991-01-10 | Akzo N.V. | Serpin variants |
EP0568833A1 (en) * | 1992-04-10 | 1993-11-10 | Eisai Co., Ltd. | Human antithrombin III mutants |
JPH0971600A (ja) * | 1995-09-06 | 1997-03-18 | Eisai Co Ltd | ヒトアンチトロンビンiii 変異体 |
WO1999064568A1 (fr) * | 1998-06-08 | 1999-12-16 | Universite De Nantes | Kit d'encapsidation |
Non-Patent Citations (5)
Title |
---|
FUTAMURA A. ET AL.: "Serine 380(P14)->glutamate mutation activates antithrombin as an inhibitor of factor Xa", J. BIOL. CHEM., vol. 275, no. 6, February 2000 (2000-02-01), pages 4092 - 4098, XP002931758 * |
HUNTINGTON J.A. ET AL.: "Conformational conversion of antithrombin to a fully activated substrate of factor Xa without need for heparin", BIOCHEMISTRY, vol. 37, no. 10, 1998, pages 3272 - 3277, XP002931756 * |
HUNTINGTON J.A. ET AL.: "Mechanism of heparin activation of antithrombin. Evidence for reactive ce ter loop preinsertion with expulsion upon heparin binding", BIOCHEMISTRY, vol. 35, no. 26, 1996, pages 8495 - 8503, XP002931757 * |
MEAGHER J.L. ET AL.: "Deconvolution of the fluorescence emission spectrum of human antithrombin and identification of the tryptophan residues that are responsive to heparin binding", J. BIOL. CHEM., vol. 273, no. 36, 1998, pages 23283 - 23289, XP002931759 * |
SHIRK R.A. ET AL.: "Role of the H helix in heparin binding to protein C inhibitor", J. BIOL. CHEM., vol. 269, no. 46, 1994, pages 28690 - 28695, XP002931760 * |
Also Published As
Publication number | Publication date |
---|---|
KR100798285B1 (ko) | 2008-01-28 |
EP1225184B1 (en) | 2008-03-12 |
KR20070085485A (ko) | 2007-08-27 |
ES2303508T3 (es) | 2008-08-16 |
CA2375224C (en) | 2010-10-12 |
CA2375224A1 (en) | 2000-12-28 |
AU5568100A (en) | 2001-01-09 |
US7001993B1 (en) | 2006-02-21 |
EP1225184A4 (en) | 2003-01-15 |
ATE388965T1 (de) | 2008-03-15 |
DE60038310T2 (de) | 2009-04-09 |
AU776796B2 (en) | 2004-09-23 |
KR20020011444A (ko) | 2002-02-08 |
JP2001000191A (ja) | 2001-01-09 |
JP4339962B2 (ja) | 2009-10-07 |
EP1225184A1 (en) | 2002-07-24 |
KR100832733B1 (ko) | 2008-05-27 |
DE60038310D1 (de) | 2008-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0487591B1 (en) | Anticoagulant protein | |
AU676145B2 (en) | A human kunitz-type protease inhibitor variant | |
Scacheri et al. | Novel hirudin variants from the leech Hirudinaria manillensis: amino acid sequence, cDNA cloning and genomic organization | |
JP3345420B2 (ja) | 新規のヒトクニツ型プロテアーゼインヒビター及びその変異体 | |
EP0832232A1 (en) | Kunitz type plasma kallikrein inhibitors | |
NZ246570A (en) | Variant polypeptides of human kunitz type protease inhibitor domain 1 of tissue factor pathway inhibitor and compositions thereof | |
NZ246567A (en) | Variant polypeptides of a human kunitz type protease inhibitor domain and pharmaceutical compositions thereof | |
WO2000078811A1 (fr) | Variants d'antithrombine humaine | |
US5876971A (en) | Thrombin inhibitor from the saliva of protostomia | |
Dodt et al. | Thrombin inhibitors of bloodsucking animals | |
Stone et al. | Molecular basis for the inhibition of thrombin by hirudin | |
Day et al. | Bacterial expression, purification, and partial characterization of amino acids 94–155 of human tissue factor pathway inhibitor (TFPI) as an inhibitor of blood coagulation factor Xa | |
WO2002014514A1 (en) | A fibrinogen clotting inhibitor derived from snake venom and process for preparing the same | |
WO1999060126A9 (en) | Protein z-dependent protease inhibitor | |
SRL | Novel hirudin variants from the leech Hirudinaria manillensis. Amino acid sequence, cDNA cloning and genomic organization. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 55681/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2375224 Country of ref document: CA Ref country code: CA Ref document number: 2375224 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017016463 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017016463 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000940809 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10018815 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000940809 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 55681/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000940809 Country of ref document: EP |